Tabernanthalog
From Wikipedia, the free encyclopedia
Pharmaceutical compound
Other namesTBG; DLX-007; DLX007
Drug classNon-selective serotonin receptor modulator; Non-hallucinogenic serotonin 5-HT2A receptor partial agonist
ATC code
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | TBG; DLX-007; DLX007 |
| Routes of administration | Oral[1] |
| Drug class | Non-selective serotonin receptor modulator; Non-hallucinogenic serotonin 5-HT2A receptor partial agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H18N2O |
| Molar mass | 230.311 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure.[2][3] It was developed by David E. Olson and colleagues at the University of California, Davis.[3] The drug is being developed by Delix Therapeutics as a potential pharmaceutical drug for treatment of neuropsychiatric disorders.[1][4] However, as of January 2026, tabernanthalog has still yet to enter clinical trials.[5]
There have been informal anecdotal reports of the effects of tabernanthalog.[6][7][5][8]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 39% BI @ 10 μM 14,600 (EC50Tooltip half-maximal effective concentration) 95% (EmaxTooltip maximal efficacy) |
| 5-HT1B | 66% BI @ 10 μM 34 (EC50) 87% (Emax) |
| 5-HT1D | ND (Ki) 2,180 (EC50) 76% (Emax) |
| 5-HT1E | ND (Ki) 2,784 (EC50) 117% (Emax) |
| 5-HT1F | ND (Ki) 40 (EC50) 64% (Emax) |
| 5-HT2A | 4,440 (Ki) 57% BI @ 10 μM 147–4,570 (EC50) 8–91% (Emax) |
| 5-HT2B | 439 (Ki) 86% BI @ 10 μM 2,827 or IA (EC50) 46% or IA (Emax) |
| 5-HT2C | 28,590 (Ki) 99% BI @ 10 μM 13–69 (EC50) 21–99% (Emax) |
| 5-HT3 | 14% BI @ 10 μM |
| 5-HT4 | ND (Ki) >10,000 (EC50) |
| 5-HT5A | ND (Ki) >10,000 (EC50) |
| 5-HT6 | ND (Ki) 132–214 (EC50) 88–133% (Emax) |
| 5-HT7 | ND (Ki) >10,000 (EC50) |
| α1A–α1D | 15–20% BI @ 10 μM |
| α2A | 81% BI @ 10 μM |
| α2B | 27% BI @ 10 μM |
| α2C | ND |
| β1–β2 | 9% BI @ 10 μM |
| D1, D2 | 3–18% BI @ 10 μM |
| D3–D5 | ND |
| H1 | 35% BI @ 10 μM |
| H2 | –12% BI @ 10 μM |
| H3, H4 | ND |
| M1–M4 | 2–18% BI @ 10 μM |
| M5 | ND |
| nAChTooltip Nicotinic acetylcholine receptor | 16–19% BI @ 10 μM |
| I1, I2 | ND |
| σ1, σ2 | ND |
| MORTooltip μ-Opioid receptor | 17% BI @ 10 μM IA (EC50) |
| DORTooltip δ-Opioid receptor | 14% BI @ 10 μM IA (EC50) |
| KORTooltip κ-Opioid receptor | 7% BI @ 10 μM >10,000 (EC50) |
| NMDARTooltip N-Methyl-D-aspartate receptor | 0–3% BI @ 10 μM (rat) |
| TAAR1Tooltip Trace amine-associated receptor 1 | ND |
| SERTTooltip Serotonin transporter | 88% BI @ 10 μM 600 (IC50Tooltip half-maximal inhibitory concentration) |
| NETTooltip Norepinephrine transporter | ND (Ki) 5,400 (IC50) |
| DATTooltip Dopamine transporter | ND (Ki) 65,000 (IC50) |
| VMATTooltip Vesicular monoamine transporter | 10% BI @ 10 μM |
| MAO-ATooltip Monoamine oxidase A | 66% BI @ 10 μM 15,100 (IC50) |
| MAO-BTooltip Monoamine oxidase B | 16% BI @ 10 μM 28% FI @ 100 μM |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [3][9][2][10][11][12] | |
Tabernanthalog is a non-selective and non-psychedelic serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2C, and 5-HT6 receptors and as an agonist or antagonist of the serotonin 5-HT2B receptor.[3][9][11] It also shows significant binding to the serotonin transporter (SERT) (acting as a serotonin reuptake inhibitor), the α2A-adrenergic receptor, and monoamine oxidase A (MAO-A).[3] In contrast to iboga alkaloids like ibogaine and noribogaine, tabernanthalog showed negligible interactions with opioid receptors, the NMDA receptor, and certain nicotinic acetylcholine receptors.[3] However, in subsequent research, it weakly inhibited certain nicotinic acetylcholine receptors, as well as, to a much lesser extent, the GABAA receptor.[13] Tabernanthalog was found to be 100-fold less potent at the hERG antitarget compared to ibogaine, and hence is thought to have a much lower potential for cardiotoxicity.[3]
Tabernanthalog did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence appears to be non-hallucinogenic.[3] However, it was found to promote structural neuroplasticity (i.e., to act as a psychoplastogen), reduce drug-seeking behavior, and produce antidepressant-like effects.[3][14][15][16] It has also been shown that it reduces motivation for heroin and alcohol in rodents.[16]
History
Tabernanthalog was first described in the scientific literature by David E. Olson and colleagues at the University of California, Davis in January 2021.[3][17]
Society and culture
Grey market use
Tabernanthalog has been known to be sold online by research chemical vendors for purposes such as "nootropic" use.[7]
Legal status
Canada
Tabernanthalog is not a controlled substance in Canada.[18]
United States
Tabernanthalog is not an explicitly controlled substance in the United States.[19]
Research
Tabernanthalog is under development for the treatment of central nervous system disorders (CNS disorders).[1][20] It is being developed by Delix Therapeutics.[1][20] As of May 2025, no recent development has been reported.[1] It had reached the preclinical research stage of development.[1][20] A phase 1 clinical trial was being planned for the first half of 2023.[1] Delix Therapeutics also partnered with National Institute on Drug Abuse (NIDA) to evaluate tabernanthalog for the treatment of substance-related disorders in December 2021.[1] As of January 2026, tabernanthalog has still yet to enter clinical trials.[5]
See also
References
- 1 2 3 4 5 6 7 8 "DLX 7". AdisInsight. 28 May 2025. Retrieved 31 July 2025.
- 1 2 Sharp T, Ippolito A (May 2025). "Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists". Br J Pharmacol bph.70050. doi:10.1111/bph.70050. PMID 40405723.
- 1 2 3 4 5 6 7 8 9 10 Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. (January 2021). "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature. 589 (7842): 474–479. Bibcode:2021Natur.589..474C. doi:10.1038/s41586-020-3008-z. PMC 7874389. PMID 33299186.
- ↑ Grace B (6 March 2021). "Can we take the high out of psychedelics?". Wired. Retrieved 12 July 2022.
- 1 2 3 Martínez, Sergio Lázaro (27 January 2026). "The Perils of Non-Hallucinogenic Claims: On the Limits of Translatability". OPEN Foundation. Retrieved 1 April 2026.
- ↑ Love, Shayla (20 October 2024). "Tripping on Nothing". The Atlantic.
{{cite web}}: CS1 maint: deprecated archival service (link) - 1 2 Hardman, Josh (19 July 2023). "Non-Hallucinogenic Trip Reports: Searching for the Tabernanthalog Tasters". Psychedelic Alpha. Retrieved 14 October 2025.
- ↑ Juliani, Arthur (30 December 2023). "A Phenomenological Report on the Novel Non-Hallucinogenic Psychedelic Tabernanthalog". Medium. Retrieved 14 October 2025.
{{cite web}}: CS1 maint: deprecated archival service (link) - 1 2 Arias HR, Micheli L, Rudin D, Bento O, Borsdorf S, Ciampi C, Marin P, Ponimaskin E, Manetti D, Romanelli MN, Ghelardini C, Liechti ME, Di Cesare Mannelli L (August 2024). "Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT2A receptor activation". Biomed Pharmacother. 177 116867. doi:10.1016/j.biopha.2024.116867. hdl:2158/1371514. PMID 38889634.
- ↑ Ippolito A, Vasudevan S, Hurley S, Gilmour G, Westhorpe F, Churchill G, Sharp T (June 2025). "Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs". Br J Pharmacol bph.70109. doi:10.1111/bph.70109. PMID 40545270.
- 1 2 Arias HR, Rudin D, Luethi D, Valenta J, Leśniak A, Czartoryska Z, Olejarz-Maciej A, Doroz-Płonka A, Manetti D, De Deurwaerdère P, Romanelli MN, Handzlik J, Liechti ME, Chagraoui A (January 2025). "The psychoplastogens ibogaminalog and ibogainalog induce antidepressant-like activity in naïve and depressed mice by mechanisms involving 5-HT2A receptor activation and serotonergic transmission". Prog Neuropsychopharmacol Biol Psychiatry. 136 111217. doi:10.1016/j.pnpbp.2024.111217. PMID 39662723.
- ↑ Arias HR, Micheli L, Jensen AA, Galant S, Vandermoere F, Venturi D, Manetti D, Romanelli MN, Ghelardini C, Marin P, Di Cesare Mannelli L (March 2025). "Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT2A and mGlu2 receptors". Biomed Pharmacother. 184 117887. doi:10.1016/j.biopha.2025.117887. hdl:2158/1423286. PMID 39938347.
- ↑ Tae HS, Ortells MO, Yousuf A, Xu SQ, Akk G, Adams DJ, Arias HR (May 2024). "Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABAA receptor and CaV2.2 channel". Biochem Pharmacol. 223 116183. doi:10.1016/j.bcp.2024.116183. PMC 11151864. PMID 38580167.
- ↑ Lu J, Tjia M, Mullen B, Cao B, Lukasiewicz K, Shah-Morales S, et al. (November 2021). "An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress". Molecular Psychiatry. 26 (11): 6237–6252. doi:10.1038/s41380-021-01159-1. PMC 8613316. PMID 34035476.
- ↑ Peters J, Olson DE (20 July 2021). "Engineering Safer Psychedelics for Treating Addiction". Neuroscience Insights. 16 26331055211033847. doi:10.1177/26331055211033847. PMC 8295933. PMID 34350400.
- 1 2 Heinsbroek JA, Giannotti G, Bonilla J, Olson DE, Peters J (June 2023). "Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model". Psychedelic Medicine. 1 (2): 111–119. doi:10.1089/psymed.2023.0009. PMC 10286262. PMID 37360328.
- ↑ Jaster, Alaina M. (13 January 2021). "Researchers Synthesize Novel Compound, Tabernanthalog, a Non-Hallucinogenic Ibogaine Analog". Psychedelic Science Review. Retrieved 14 October 2025.
- ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. 5 December 2025. Retrieved 20 January 2026.
- ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
- 1 2 3 "Delving into the Latest Updates on DLX-7 with Synapse". Synapse. 7 August 2025. Retrieved 14 October 2025.
External links
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||||||||
| α1 |
| ||||
|---|---|---|---|---|---|
| α2 |
| ||||
| β |
| ||||
| nAChRsTooltip Nicotinic acetylcholine receptors |
| ||||
|---|---|---|---|---|---|
| Precursors (and prodrugs) | |||||
| DATTooltip Dopamine transporter (DRIsTooltip Dopamine reuptake inhibitors) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NETTooltip Norepinephrine transporter (NRIsTooltip Norepinephrine reuptake inhibitors) |
| ||||||||||||||
| SERTTooltip Serotonin transporter (SRIsTooltip Serotonin reuptake inhibitors) |
| ||||||||||||||
| VMATsTooltip Vesicular monoamine transporters | |||||||||||||||
| Others |
| ||||||||||||||
| Tryptamines |
|
|---|---|
| 4-Hydroxytryptamines and esters/ethers |
|
| 5-Hydroxy- and 5-methoxytryptamines |
|
| N-Acetyltryptamines |
|
| α-Alkyltryptamines |
|
| α-Ketotryptamines | |
| Cyclized tryptamines |
|
| Isotryptamines | |
| Related compounds |
|